secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001933414-23-000081
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys presents post-hoc analysis linking BMI to enhanced BP reduction with lorundrostat
--------------------------------------------------------------------------------

- Post-hoc analysis from Target-HTN Phase 2 trial: median systolic BP reduction of 32 mmHg in responder population.
- Enhanced response proportional to BMI; modeled reduction ~12 mmHg at BMI 30 and ~19 mmHg at BMI 40 kg/m².
- Statistically significant linear regression association between BMI and systolic BP reduction (BMI 22.5-40 kg/m²).
- Advance-HTN pivotal trial enrolling; Phase 3 Launch-HTN trial expected to start before end of 2023.
- Data supports obesity-associated aldosterone-dependent hypertensive endotype as predictor of response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000081/0001933414-23-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000081/mlys-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001933414-23-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer